AU2013228096B2 - Methods and compositions for stabilizing dried biological materials - Google Patents

Methods and compositions for stabilizing dried biological materials Download PDF

Info

Publication number
AU2013228096B2
AU2013228096B2 AU2013228096A AU2013228096A AU2013228096B2 AU 2013228096 B2 AU2013228096 B2 AU 2013228096B2 AU 2013228096 A AU2013228096 A AU 2013228096A AU 2013228096 A AU2013228096 A AU 2013228096A AU 2013228096 B2 AU2013228096 B2 AU 2013228096B2
Authority
AU
Australia
Prior art keywords
formulation
biopharmaceutical
agent
drying
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013228096A
Other languages
English (en)
Other versions
AU2013228096A1 (en
Inventor
Jean-Pierre Amorij
Heleen KRAAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intravacc BV
Original Assignee
Intravacc BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intravacc BV filed Critical Intravacc BV
Publication of AU2013228096A1 publication Critical patent/AU2013228096A1/en
Application granted granted Critical
Publication of AU2013228096B2 publication Critical patent/AU2013228096B2/en
Assigned to INTRAVACC B.V. reassignment INTRAVACC B.V. Request for Assignment Assignors: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013228096A 2012-03-05 2013-03-05 Methods and compositions for stabilizing dried biological materials Ceased AU2013228096B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261606577P 2012-03-05 2012-03-05
US61/606,577 2012-03-05
EP12158086.4 2012-03-05
EP12158086 2012-03-05
PCT/NL2013/050139 WO2013133702A1 (en) 2012-03-05 2013-03-05 Methods and compositions for stabilizing dried biological materials

Publications (2)

Publication Number Publication Date
AU2013228096A1 AU2013228096A1 (en) 2014-09-11
AU2013228096B2 true AU2013228096B2 (en) 2017-07-13

Family

ID=49117091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013228096A Ceased AU2013228096B2 (en) 2012-03-05 2013-03-05 Methods and compositions for stabilizing dried biological materials

Country Status (11)

Country Link
US (2) US9827303B2 (enExample)
EP (1) EP2822540B1 (enExample)
JP (1) JP6253161B2 (enExample)
KR (1) KR102108876B1 (enExample)
CN (1) CN104271119B (enExample)
AU (1) AU2013228096B2 (enExample)
BR (1) BR112014020930A2 (enExample)
CA (1) CA2865551C (enExample)
IN (1) IN2014MN01714A (enExample)
WO (1) WO2013133702A1 (enExample)
ZA (1) ZA201407198B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
WO2015097650A1 (en) 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
MA45381A (fr) * 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
KR102284550B1 (ko) * 2017-02-24 2021-07-30 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 디바이스의 제조 방법
US20200085941A1 (en) * 2017-04-28 2020-03-19 Universal Stabilization Technologies, Inc. Antigenic thermostable polio vaccines & related methods
MX2020000480A (es) * 2017-07-11 2020-09-10 Universal Stabilization Tech Inc Método para la conservación de material biológico.
CN111166891B (zh) * 2018-11-13 2022-04-05 中国药科大学 甘露醇共晶辅料及其制备方法和用途
CN112111609A (zh) * 2020-10-29 2020-12-22 上海伯杰医疗科技有限公司 一种肠道病毒通用型核酸检测试剂盒
CN114748615A (zh) * 2022-04-29 2022-07-15 成都安永鼎业生物技术有限公司 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途
CN115089864B (zh) * 2022-07-14 2023-12-29 复旦大学 一种使用冷冻干燥技术制备可溶性微针贴片的方法
CN116763914B (zh) * 2023-02-06 2024-02-23 广东永顺生物制药股份有限公司 猪瘟、高致病性猪繁殖与呼吸综合征二联耐热保护剂活疫苗及其制备方法
CN117482072A (zh) * 2023-11-17 2024-02-02 上海市浦东新区公利医院(第二军医大学附属公利医院) 山梨糖醇在制备治疗呼吸道合胞病毒所致疾病的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500512A (en) * 1981-05-13 1985-02-19 Institut Pasteur Stabilizing agents for live viruses for preparing vaccines, and stabilized vaccines containing said stabilizing agents
WO1999012568A1 (en) * 1997-09-05 1999-03-18 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US20080311078A1 (en) * 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
EP2322211A1 (en) * 2005-02-17 2011-05-18 GlaxoSmithKline Biologicals S.A. Live attenuated rotavirus vaccine for oral administration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
DE69738271T2 (de) * 1996-09-26 2008-08-28 Merck & Co., Inc. Rotavirus-impfstoff
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
EP1289494A2 (en) * 2000-06-08 2003-03-12 Powderject Vaccines, Inc. Powder compositions
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
CA2549197C (en) * 2003-12-17 2015-04-14 Wyeth Methods for producing storage stable viruses and immunogenic compositions thereof
AU2004303719B2 (en) 2003-12-24 2010-11-11 Intravacc B.V. A respiratory syncytial virus with a genomic deficiency complemented in trans
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
TR201906255T4 (tr) * 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500512A (en) * 1981-05-13 1985-02-19 Institut Pasteur Stabilizing agents for live viruses for preparing vaccines, and stabilized vaccines containing said stabilizing agents
WO1999012568A1 (en) * 1997-09-05 1999-03-18 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EP2322211A1 (en) * 2005-02-17 2011-05-18 GlaxoSmithKline Biologicals S.A. Live attenuated rotavirus vaccine for oral administration
US20080311078A1 (en) * 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations

Also Published As

Publication number Publication date
CN104271119A (zh) 2015-01-07
CN104271119B (zh) 2018-07-10
KR20150008848A (ko) 2015-01-23
EP2822540A1 (en) 2015-01-14
KR102108876B1 (ko) 2020-05-12
AU2013228096A1 (en) 2014-09-11
EP2822540B1 (en) 2020-04-08
CA2865551A1 (en) 2013-09-12
ZA201407198B (en) 2016-02-24
US20180055924A1 (en) 2018-03-01
CA2865551C (en) 2021-01-12
US20150030629A1 (en) 2015-01-29
US10335479B2 (en) 2019-07-02
JP2015509529A (ja) 2015-03-30
BR112014020930A2 (pt) 2017-06-27
JP6253161B2 (ja) 2017-12-27
US9827303B2 (en) 2017-11-28
IN2014MN01714A (enExample) 2015-05-29
WO2013133702A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
US10335479B2 (en) Methods and compositions for stabilizing dried biological materials
Dumpa et al. Stability of vaccines
JP7358068B2 (ja) 熱安定性ワクチン製剤及びマイクロニードル
TW202309276A (zh) 用於與經改良之調配物一起穩定黃病毒的組成物及方法
US10532093B2 (en) Thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
KR20010082233A (ko) 동결 건조된 ａ형 간염의 감독된 생 백신 및 그의 안정화제
US10806781B2 (en) Compositions and methods for live, attenuated alphavirus formulations
WO2012028315A1 (en) A stabilizer for the preparation of a dry polio injectable vaccine composition
Zuo et al. Live vaccine preserved at room temperature: Preparation and characterization of a freeze-dried classical swine fever virus vaccine
ES2788324T3 (es) Métodos y composiciones para estabilizar materiales biológicos secos
EA046342B1 (ru) Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус и процесс их приготовления
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired